Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial | Zendy

Samuel A. Wells | Zendy; Bruce G. Robinson | Zendy; Robert F. Gagel | Zendy; Henning Dralle | Zendy; James A. Fagin | Zendy; Massimo Santoro | Zendy; Éric Baudin | Zendy; Rossella Elisei | Zendy; Barbara Jarząb | Zendy; James R. Vasselli | Zendy; Jessica Read | Zendy; Peter Langmuir | Zendy; Anderson J. Ryan | Zendy; Martin Schlumberger | Zendy

Open Access

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

Author(s) -

Samuel A. Wells,

Bruce G. Robinson,

Robert F. Gagel,

Henning Dralle,

James A. Fagin,

Massimo Santoro,

Éric Baudin,

Rossella Elisei,

Barbara Jarząb,

James R. Vasselli,

Jessica Read,

Peter Langmuir,

Anderson J. Ryan,

Martin Schlumberger

Publication year - 2011

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2011.35.5040

Subject(s) - vandetanib , medicine , placebo , medullary thyroid cancer , oncology , hazard ratio , gastroenterology , clinical endpoint , adverse effect , cancer , urology , randomized controlled trial , thyroid cancer , pathology , confidence interval , tyrosine kinase , receptor , alternative medicine

There is no effective therapy for patients with advanced medullary thyroid carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular endothelial growth factor receptor, and epidermal growth factor receptor signaling, has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research